Lv6
2470 积分 2022-02-25 加入
Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib
8天前
已完结
Comment on “Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database”
11天前
已完结
Author’s Response to: Comment on “Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database” and “Critical Evaluation of Methodological Approaches in ALK TKI Research: Addressing Confounding Factors and Statistical Robustness”
11天前
已关闭
New promises and challenges in the treatment of advanced non-small-cell lung cancer
24天前
已完结
PFS, OS or toxicity: What is the most important factor in the treatment of EGFR-mutated lung cancer?
25天前
已关闭
Inoperable Stage III EGFR Mutant Non-Small Cell Lung Cancer: time for drug first, local later?
25天前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
2个月前
已完结
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
3个月前
已完结
Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study
3个月前
已关闭
Outcomes of adjuvant whole-brain radiotherapy versus hypofractionated stereotactic radiotherapy after surgical resection of brain metastases: a propensity score-matched analysis
3个月前
已关闭
皖公网安备34019202002308
